Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy|
|Citation:||Haematologica, 2013; 98(2):193-200|
|Publisher:||Ferrata Storti Foundation|
|Sabrina Angelini, Simona Soverini, Gloria Ravegnini, Matt Barnett, Eleonora Turrini, Mark Thornquist, Fabrizio Pane, Timothy P. Hughes, Deborah L. White, Jerald Radich, Dong Wook Kim, Giuseppe Saglio, Daniela Cilloni, Ilaria Iacobucci, Giovanni Perini, Richard Woodman, Giorgio Cantelli-Forti, Michele Baccarani, Patrizia Hrelia, Giovanni Martinelli|
|Abstract:||Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent results. However, only a proportion of patients achieve major molecular response – hence the need to find biological predictors of outcome to select the optimal therapeutic strategy now that more potent inhibitors are available. We investigated a panel of 20 polymorphisms in seven genes, potentially associated with the pharmacogenetics of imatinib, in a subset of 189 patients with newly diagnosed chronic myeloid leukemia enrolled in the TOPS trial. The analysis included polymorphisms in the transporters hOCT1, MDR1, ABCG2, OCTN1, and OATP1A2, and in the metabolizing genes CYP3A4 and CYP3A5. In the overall population, the OCTN1 C allele (rs1050152), a simple combination of polymorphisms in the hOCT1 gene and another combination in the genes involved in imatinib uptake were significantly associated with major molecular response. The combination of polymorphisms in imatinib uptake was also significantly associated with complete molecular response. Analyses restricted to Caucasians highlighted the significant association of MDR1 CC (rs60023214) genotype with complete molecular response. We demonstrate the usefulness of a pharmacogenetic approach for stratifying patients with chronic myeloid leukemia according to their likelihood of achieving a major or complete molecular response to imatinib. This represents an attractive opportunity for therapy optimization, worth testing in clinical trials.|
|Keywords:||Humans; Benzamides; Piperazines; Pyrimidines; Cytochrome P-450 Enzyme System; Cation Transport Proteins; Organic Cation Transport Proteins; Antineoplastic Agents; Protein Kinase Inhibitors; Treatment Outcome; Genotype; Polymorphism, Single Nucleotide; Alleles; Adolescent; Adult; Aged; Middle Aged; Female; Male; Cytochrome P-450 CYP3A; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Young Adult; Imatinib Mesylate; ATP Binding Cassette Transporter, Subfamily B, Member 1|
|Rights:||©2013 Ferrata Storti Foundation|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.